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Abstract
Gastroesophageal reflux disease (GERD) has become the most commonly seen gastrointestinal 
disorder in outpatient clinics. In the United States, around 20% of the general population 
experience heartburn on a weekly basis. Although clinical complaints can be mild or moderate, 
patients with GERD may develop further complications, such as peptic strictures, Barrett's 
esophagus (BE), and even esophageal adenocarcinoma (EAC). Pathologically, GERD is developed 
as a result of chronic and enhanced exposure of the esophageal epithelium to noxious gastric 
refluxate. In this review article, we provide an overview of GERD, and then focus on the roles of 
stromal cells, interleukin 4 (IL-4), and adiponectin in GERD and BE. The importance of 
inflammation and immunomodulators in GERD pathogenesis is highlighted. Targeting the 
immunomodulators or inflammation in general may improve the therapeutic outcome of GERD, in 
particular, in those refractory to proton pump inhibitors.
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Gastroesophageal reflux disease (GERD) is a common disorder, affecting 18.1–27.8% of the 
population in the United States.1,a Epidemiologic studies strongly suggest that the 
prevalence of GERD is increasing, especially compared with the prevalence found in studies 
published in 1992 (approximately 13.2%).2 GERD is also increasingly prevalent in Asia, 
with a prevalence of approximately 8%.1 GERD is mainly treated with lifestyle 
modifications, pharmacotherapy, and occasionally antireflux surgery. A recent meta-analysis 
of the role of lifestyle intervention has shown that weight loss and tobacco smoking 
cessation significantly reduced esophageal acid exposure. Avoiding late evening meals and 
head-of-the-bed elevation also modified supine acid exposure.3
Pharmacotherapy, especially antacid therapy with proton pump inhibitors (PPIs), remains the 
mainstay in the management of GERD4,5 (Fig. 1). Ever since their introduction in the late 
1980s, PPIs have revolutionized the management of GERD and peptic ulcer disease, with 
substantial reductions in morbidity and mortality. Their efficacy and safety have been proved 
in long-term clinical follow-up studies.6,7 In the past three decades, PPIs have been among 
the most commonly prescribed medications worldwide. In fact, PPIs tend to be overused and 
overdosed due to the over-the-counter availability. However, as many as 10–40% of patients 
find their reflux symptoms inadequately controlled, especially at night.8,9 Poor patient 
compliance, reduced PPI bioavailability, weakly acidic or non-acidic reflux, nocturnal 
breakthrough, esophageal hypersensitivity, functional gastrointestinal disorders, and even 
mental disorders may all contribute to PPI failures.8,10,11 For those who do respond to PPI 
therapy, long-term treatment with PPIs not only generates a financial burden, but may also 
produce side effects. For example, PPIs have been showed to promote cancer promotion in 
animal models owing to hypergastrinemia12,13 or CYP1A1 induction.14 Hypochlorhydria is 
likely to cause nutritional malabsorption and, subsequently, increased risks of bone fracture, 
bacterial infections, and interstitial nephritis. Drug–drug interactions, for example, 
interference with the antiplatelet effect of clopidogrel, may also be a concern of clinical 
significance.15–17 Therefore, it is still quite important to study the mechanisms of GERD 
and its complications, Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC), and 
to develop additional treatment modalities. It should be noted that putative risks associated 
with PPIs are often based on observational epidemiological studies with low odds ratios, and 
should not be exaggerated.
The esophageal defense mechanism is made up of pre-epithelial defense, epithelial defense, 
and postepithelial defense. Pre-epithelial defense relies on esophageal clearance by 
peristalsis and gravity and the buffer supplied by the saliva and esophageal submucosal 
glands. The combination of apical junction complexes and apical cell membranes of cells 
within the stratum corneum largely accounts for the defensive ability of esophageal 
epithelium.18 The apical junction complexes are highly complex organelles, including tight 
aThe first five paragraphs of this manuscript share the research idea in our previous review article published as Ref. 118.
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junctions, adherens junctions, and desmosomes.19,20 For tight junctions in esophageal 
epithelium, occludin and claudins (CLDNs) are the major proteins bridging the intercellular 
space, with CLDN1 and CLDN4 being the most highly expressed.21,22 In adherens 
junctions, E-cadherin is the major bridging protein,23 and, in desmosomes, desmogleins and 
desmocollin are the major ones.24
In the presence of gastroesophageal reflux, the esophageal epithelium responds to the acidic 
injury with altered apical junction complexes, increased paracellular permeability, and 
dilated intercellular space.25 These morphological changes are often due to changes in the 
expression and localization of tight junction proteins (occludin, CLDN1, CLDN4), the 
number of desmosomes, and cleavage of the adherens junction protein E-cadherin.26–30 
CLDN4 is believed to be a major tight junction protein contributing to barrier function in 
esophageal squamous epithelium, because CLDN4 overexpression in MDCK II cells 
increases epithelial resistance and lowers paracellular permeability for cations.21,31 CLDN4 
deficiency causes urothelial hyperplasia and progressive hydronephrosis.32 CLDN1 
deficiency causes postnatal death due to skin barrier defect to the water loss.33 However, 
esophageal phenotypes in CLDN1- or CLDN4-deficient mice have not been reported.
Following the initial change in the esophageal epithelium, inflammation takes place in the 
esophageal epithelium.34,35 Using surgical models of gastroesophageal reflux in rats, we 
have clearly shown that anti-inflammatory agents have chemopreventive effects on 
adenocarcinoma.36–38 In humans, the use of aspirin or nonsteroidal anti-inflammatory drugs 
(NSAIDs) is associated with lower risk of BE and EAC, although long-term double-blind 
clinical trials are still needed to validate this conclusion.39 Mechanistically, inflammation is 
triggered by the release of various immunomodulators when cells are stimulated by reflux. 
Inflammation promotes and perpetuates injury of the esophageal epithelium directly by 
attenuating epithelial barrier function and indirectly by altering neuromuscular transmission 
of esophageal smooth muscle. In addition to inflammation, oxidative stress subsequent to 
reflux also induces dilated intercellular space and impairs the barrier function.40–42 Once 
inflammation becomes chronic, it reduces lower esophageal sphincter pressure, impairs 
peristaltic contractility, contracts the longitudinal muscle, and promotes the formation of 
hiatal hernia. It is very likely that a vicious cycle is formed between inflammation and 
epithelial injury to facilitate GERD pathogenesis (Fig. 2).
In this review, we focus on three major players in the pathogenesis of GERD and its 
complications. Stromal cells are major producers of immunomodulators apart from epithelial 
cells. Interleukin 4 (IL-4) is one of the proinflammatory cytokines that participates in 
intestinal metaplasia. As an anti-inflammatory adipokine secreted by adipose tissues, low 
adiponectin partially explains how obesity contributes to GERD and its complications.
Stromal cells
The importance of the stroma in maintaining epithelial integrity, contributing to wound 
healing, and promoting the tumor microenvironment has been established in a number of 
tissues. The complex stromal microenvironment contains several cell types, including 
fibroblasts, smooth muscle cells, immune and inflammatory cells, and endothelial cells.43 
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Under normal conditions, fibroblasts have a low proliferative index and primarily secrete 
factors necessary to maintain tissue homeostasis. In the wound-repair response, activated 
fibroblasts are characterized by high proliferative index, synthesis of extracellular matrix, 
and secretion of growth factors and remodeling enzymes necessary for tissue repair. This 
activation is self-limited, however, and once the wound is healed, activated fibroblasts revert 
to their quiescent state. In cancer, the stroma remains reactive and promotes tumor growth 
and invasion.43–45 The cellular and molecular mechanisms mediating wound healing, repair, 
and malignancy in the esophagus are topics of ongoing investigation.
Several lines of evidence support a broad range of activity for esophageal stromal cells, 
including modulation of mucosal damage and effects on esophageal motility. Evidence from 
work in other organ systems suggests that the main effector cells in the esophagus are likely 
mesenchymal cell derivatives, such as fibroblasts, myofibroblasts, and smooth muscle 
cells.46 In response to an inflammatory environment, stromal cells, such as fibroblasts, 
expand in number (proliferate) and migrate toward a chemotactic gradient.46 Molecules 
inducing migration include fibronectin, platelet-derived grown factor (PDGF)-A and PDGF-
B, insulin-like growth factor 1 (IGF-1), and epidermal growth factor (EGF).46 In 
eosinophilic esophagitis, subepithelial fibrosis is thought to be a major cause of dysphagia. 
Elevated T helper 2 cytokines, the profibrotic mediator TGF-β1, and eosinophil products 
induce fibrogenesis via induction of esophageal fibroblast production and secretion of 
fibronectin and collagen I.47 In addition, incubation of fibroblasts with eosinophil products 
promotes eosinophil binding via increased expression of vascular cell adhesion molecule 1 
(VCAM-1).48 An increase in a large number of cytokines and chemokines has been detected 
in mucosal biopsy specimens of GERD patients, including IL-1β, IL-6, IL-8, IL-10, 
interferon γ (IFNγ), monocyte chemoattractant protein 1 (MCP-1), and RANTES.46 
Cellular sources of these cytokines include epithelial cells, immune cells, and a 
heterogeneous population of stromal cells.
Myofibroblasts are a subpopulation of stromal cells best characterized in the lower 
gastrointestinal tract located at the interface between the epithelium and the lamina propria. 
Distinguishing features of these cells are a spindle-shaped morphology and expression of α-
SMA and vimentin and weak or inconsistent desmin expression.49 They participate in injury 
and repair, inflammation, and carcinogenesis, at least in part via paracrine mechanisms.50 
The importance of this population of stromal cells and the critical role of epithelial–stromal 
interactions is further demonstrated by their role in regulating epithelial cell proliferation 
and in contributing to the stem cell niche.50,51 Spindle-shaped α-SMA– and vimentin-
expressing, non-immune, non-endothelial cells have been observed near the stratified 
squamous epithelium of neonatal and adult murine esophagus52 and normal adult human 
esophagectomy specimens.53 On the basis of morphology and protein expression, these cells 
were termed myofibroblasts. Vimentin-expressing fibroblasts and endothelial cells populated 
the remainder of the subepithelial stroma of the normal human esophagus. In GERD 
esophageal biopsies with sufficient lamina propria, an increase in α-SMA+ non-endothelial 
cells, along with an increase in extracellular stromal IL-6 and nuclear factor κB (NF-κB) 
activation, was observed.53 These findings further implicated these cells in disease 
pathogenesis.
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The molecular mechanisms regulating the role of esophageal stromal cells have been 
investigated in primary cultures of fibroblasts and myofibroblasts. Primary fibroblast 
cultures derived from freshly resected human histologically normal esophagectomy 
specimens48 and subcultured in medium used for skin fibroblasts produce proinflammatory 
cytokines. Interestingly, these cells spontaneously produced low IL-6 levels, which markedly 
increased after stimulation with IFN-ɣ+ PMA and particularly with IL-1β stimulation. IL-1β 
and tumor necrosis factor α (TNF-α) were not detected in unstimulated or stimulated cell 
supernatants.48
In a separate study, esophageal stromal cells were derived from the mucosa of histologically 
normal human esophagectomy specimens. These cells were spindle shaped, expressed α-
SMA and vimentin, and lacked expression of endothelial and hematopoietic markers53 in 
primary culture and were therefore termed myofibroblasts. Immunocytochemistry and 
immunoblotting showed that human esophageal myofibroblasts expressed the putative acid 
receptor transient receptor potential channel vanilloid subfamily 1 (TRPV1).53 Increased 
TRPV1 gene and protein expression has been reported in nonerosive reflux disease and 
erosive esophagitis biopsies.54 Primary cultures of human esophageal myofibroblasts 
responded to non-cytotoxic pH-4 acidified media with IL-6 and IL-8 secretion.53 Treatment 
of esophageal myofibroblasts with the TRPV1 competitive antagonist AMG9810 inhibited 
IL-6 secretion in response to acidified media.53
Human esophageal myofibroblasts in primary culture also express the innate immune system 
activator toll-like receptor 4 (TLR4) mRNA and protein and proinflammatory cytokines in 
response to TLR4 ligands LPS and HMGB1.53 These cells secrete IL-6 in response to acid 
and TLR4 ligand injurious agents encountered in GERD via NF-κB activation.53 In this 
study, human esophageal myofibroblast secretion of IL-1β was not detected in response to 
acidified media or to TLR4 ligands.53
Expression of TLR4 has been evaluated in the human esophagus. TLR4 expression 
progressively increased from reflux esophagitis patients, to patients with BE, to those with 
EAC.44 Examination of TLR4 expression in normal and reflux esophagitis biopsies with 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and in situ 
hybridization showed a 1.9-fold increase in TLR4 expression in reflux esophagitis, largely 
confined to the basal layer of the epithelium.55 Immunostaining of normal squamous 
epithelium showed cytoplasmic expression of TLR4 in keratinocytes located at the basal 
layer of the epithelium.55 In reflux esophagitis biopsies, expression was also observed in 
more superficial epithelial layers.55 Protein expression was shown in images of lamina 
propria papillae, although this has not been explored further. The presence of lamina propria 
was not required in these biopsies, however, and therefore not specifically evaluated. In 
biopsies from BE and EAC patients, where lamina propria was readily available, however, 
nuclear and cytoplasmic TLR4 expression was present in a variety of cells, including 
inflammatory cells (plasma cells, lymphocytes), fibroblasts, muscle cells, and endothelial 
cells.55
The potential physiologic consequences of esophageal stromal cell proinflammatory 
mediator production have also been investigated. For example, the proinflammatory 
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cytokines IL-1β and IL-6 reduce esophageal circular muscle contraction in an experimental 
cat esophagitis model.56 Endoscopic mucosal biopsies from the distal human esophagus 
with esophagitis cultured on Transwell inserts demonstrate enhanced secretion of IL-1β and 
IL-6 compared with non-esophagitis mucosal biopsies.48 Furthermore, soluble products of 
mucosal organ cultures from the lower third of the esophagus from esophagitis patients 
reduced esophageal circular muscle contraction, an effect not observed using mucosa of 
patients with GERD symptoms only.48 To investigate the cellular source of these mediators, 
the effect of supernatants from untreated primary esophageal cells, including epithelial cells, 
muscle cells, and fibroblasts, on the inhibition of contraction of esophageal circular muscle 
strips was evaluated.48 Supernatants from epithelial cells were most effective at reducing 
muscle cell contractility, followed by muscle cells. Interestingly, supernatants from 
unstimulated fibroblasts had no effect on muscle cell contractility in this study. The effects 
of supernatants isolated from stimulated fibroblasts on muscle contractility were not 
examined. Furthermore, sample limitations precluded definitive identification of the secreted 
factor responsible for the effects on muscle contractility.
The concept that the esophageal stroma is more than a bystander has also been investigated 
in esophageal cancer, with evidence that the stroma is an active participant in the regulation 
of tumor invasion and progression. Fibroblasts in the tumor microenvironment are termed 
cancer-associated fibroblasts (CAFs). While the cellular origins of esophageal CAFs remain 
a topic of ongoing inquiry, potential sources are thought to include circulating mesenchymal 
stem cells, pericytes, resident tissue fibroblasts, and transdifferentiation of epithelial and 
endothelial cells.57 Studies from a number of malignancies have demonstrated that CAFs 
affect tumor growth, survival, progression, and dissemination through a variety of processes, 
including supporting tumor cell proliferation and survival through secretion of growth 
factors, tumor cell dissemination through formation of a metastatic niche, angiogenesis, 
extracellular matrix remodeling, and regulation of the innate and adaptive immune system. 
Although de novo expression of α-SMA is frequently used as a marker of CAFs, α-SMA 
does not exclusively label CAFs, and definitive markers for CAFs are still lacking.57 In the 
esophagus, the source of stromal fibroblasts (adult versus fetal) and the state of activation of 
AKT signaling are determinants of whether esophageal squamous cell tumor cells are 
invasive.58 Gene expression analysis has demonstrated that 43% of the deregulated genes 
from CAFs isolated from esophageal squamous cell carcinoma compared to adjacent non-
tumorous esophageal tissue stromal genes were associated with cell proliferation, 
extracellular matrix remodeling, and immune response, including several members of the 
Wnt family, such as WNT2.59 Wnt2 secreted from CAFs has subsequently been shown to 
promote the growth and invasion of esophageal cancer cells through activation of the 
canonical Wnt/β-catenin signaling pathway and by inducing the epithelial–mesenchymal 
transition.60 Additional studies have demonstrated that esophageal stromal fibroblasts 
mediate proliferation, angiogenesis, and invasion via autocrine and paracrine mechanisms 
involving secretion of a number of other mediators, including fibroblast grown factor (FGF), 
hepatocyte grown factor (HGF), vascular endothelial growth factors (VEGFs), TGF-β1, 
periostin, and podoplanin.44
In conclusion, several lines of evidence suggest that esophageal stromal cells have a broader 
range of activity than a simple structural role. Secreted factors from esophageal stromal cells 
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have been implicated in the pathogenesis of inflammatory esophageal disorders, such as 
GERD, eosinophilic esophagitis, and esophageal malignancy. The role of esophageal 
stromal cells as potential immunomodulators of the inflammatory response in these 
disorders therefore remains an area of intense investigation.
Interleukin 4
The prevalence of GERD is around 10%, and 2–4% of GERD patients develop BE every 10 
years.61 BE is characterized by the replacement of normal esophageal squamous epithelium 
with intestinalized columnar epithelium. BE is a premalignant condition, and BE progresses 
into EAC at a rate of 0.12–0.14% per year. There has been substantial controversy over the 
years regarding the origin of the cells of BE. The metaplastic conversion of squamous to 
columnar epithelium may develop through transdifferentiation of native squamous cells or 
through transcommitment of resident squamous stem cells. According to the stem cell 
hypothesis, stem cells may come from at least three sources: resident squamous stem cells, 
bone marrow–derived stem cells, and submucosal glandular stem cells.62 The dominant 
concept is that squamous stem cells may differentiate into columnar lineages with intestinal 
characteristics.63 The multilayered epithelium that is observed in BE has histological 
features of both squamous and columnar epithelia, and represents an early or intermediate 
stage in the development of BE, suggesting that the stratified squamous epithelium can give 
rise to BE.
Triggers of metaplastic induction of BE
Gastroesophageal reflux of acid and bile acids induces esophageal mucosal damage and an 
increase in permeability due to tight junction damage.27,64 Exposure of the stem cells to acid 
and bile acids may induce the activation of the columnar differentiation pathway. However, 
in animal models, acid reflux by itself did not induce BE.65 As reflux of acid with bile acids 
increases in BE rather than in GERD without BE, chronic reflux appears to play a crucial 
role in the development of BE.66 Previous reports indicate that acid and/or bile acids induce 
CDX2 in esophageal epithelial cells.63 The regurgitation of acid with bile acids can induce 
BE-like lesions in animal models.65
TH1 and TH2 cytokines in GERD and BE
In addition to direct stimulation by intraluminal reflux contents, the esophageal epithelial 
layer is also exposed to factors produced by chronic inflammatory cells from the basal side. 
Mucosal inflammation is a common mechanism of epithelial metaplasia in many tissues, and 
induces phenotypical changes in the cells.67 Studies have shown an increase in 
proinflammatory TH1 cytokines, including IL-1β, IL-8, IFN-γ, and TNF-α, in GERD 
compared to BE,68 whereas TH2 cytokines are predominant in BE.68,69 There is a fourfold 
increase in IL-4 in BE only. If the IL-4 level is normalized for T cell receptor expression, 
IL-4 expression increases by 100-fold in BE.68 In addition, the proportion of TH2 effector 
cells, including plasma cells and mast cells, is higher in BE than in GERD patients.69 
However, these data are observational and cannot explain the causality of IL-4 in the 
development of BE.
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A recent study using an animal model of BE showed that upregulation of IL-4 mRNA 
preceded the increase in CDX2 mRNA.70 These data indicate that IL-4 plays an important 
role in the early phase of the development of BE. It has also been reported that IL-4–
producing CD4+ T cells cause goblet cell transformation in the small intestine,71 and that T-
cells within BE tissue are mainly IL-4+CD8− cells.72 As IL-4 inhibits TH1 responses by 
inhibiting IFN-γ production and TH1 differentiation, an increase in IL-4–producing T cells 
may play a role in switching the balance from a TH1 response in GERD to a TH2 response in 
BE. However, the detailed role of these cytokines, including IL-4, in the development of BE 
remains unknown.
The roles of TH1 and TH2 cytokines in the differentiation of esophageal epithelial cells had 
not been assessed because of the lack of a research model for assessment of esophageal 
epithelial differentiation. Previous in vitro studies of esophageal epithelial differentiation 
were performed using monolayers of immortalized or cancer cell lines73 that could not 
assess metaplastic change. To address this problem, we recently developed a primary cell 
culture model of esophageal squamous epithelial cells that represents human esophageal 
epithelial layers in vivo with respect to morphology, molecular marker expression, and 
barrier function.64,74 As the origin of the cells is normal esophageal epithelium, squamous 
stem cells in the basal layers may potentially be transcommitted to columnar epithelial cells 
under certain conditions. In addition, this model makes cellular changes, such as an increase 
in cell layers, a change in basal cell morphology, and localization of specific markers, 
readily visible. We evaluated the effects of TH1 and TH2 cytokines on esophageal epithelial 
differentiation using this model. IL-4 induced columnar differentiation of the esophageal 
stratified squamous layers and induced the expression of the columnar cell markers KRT7 
and KRT8 through the JAK-PI3K pathway.75 In contrast, IL-4 decreased the expression of 
the squamous cell markers involucrin and KRT13. The columnar cell markers KRT7 and 
KRT8 are known to be expressed in BE.76 KRT7 is an early marker of GERD-related 
columnar mucosa without intestinal metaplasia.76 These data are reminiscent of the 
multilayered epithelium observed in BE patients that has both squamous and columnar 
histological features.77
Based on our in vitro study, IL-4 downregulates squamous cell differentiation and induces 
columnar-like differentiation. However, IL-4 does not induce the markers of BE, including 
CDX-2, MUC5AC, and MUC2, or the complete transdifferentiation of BE in the stratified 
squamous epithelial layers. This finding is similar to findings obtained with other factors 
that may affect the development of BE, for instance bone morphogenetic protein 4,78 which 
induces the expression of columnar types of genes in esophageal cells but does not lead to 
intestinal metaplasia.79 These data indicate that, in addition to a chronic inflammatory 
environment, other triggers, including acid and bile acids, might cooperatively induce 
metaplastic transformation.63
It is still not clear what modifies the cytokine profiles from TH1-predominant GERD to TH2-
predominant BE. An alteration of the microbiome at the distal esophagus may be one of the 
mechanisms. IL-4 induces columnar-like differentiation of esophageal squamous epithelial 
cells, irrespective of whether TH2 cytokines are the initial factors or the maintaining factors 
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in BE. Therefore, clarifying the mechanisms involved in the transition of TH1 to TH2 
cytokines in the development of BE may give us new insights for preventing BE.
In conclusion, IL-4 induces columnar-like differentiation of esophageal squamous epithelial 
cells, and IL-4 is a causal factor for the development of BE at an early phase. Therapeutic 
strategies that modulate the production of IL-4 may provide a good solution to prevent the 
development of BE and EAC.
Adiponectin
Obesity is one of the most serious public health problems worldwide, especially in 
developed countries. Obesity is defined as a body mass index equal to or higher than 30 
kg/m2.80 Previous studies have found a link between obesity and GERD, and the increasing 
incidence of GERD may be subsequent to the rising prevalence of obesity.81 More 
specifically, abdominal obesity (central obesity) has been shown to be a risk factor for 
GERD.82–87 It is believed that abdominal obesity is likely to increase intra-abdominal 
pressure owing to transmission of gravitational force of the adipose tissue to the abdominal 
cavity.88 The high abdominal pressure may lead to prolonged esophageal acid exposure 
compared with normal-weight individuals.89,90 In addition to these physical factors, obesity 
may also contribute to GERD through secretion of adipokines. Adipose tissue can secret a 
number of biologically active adipokines, such as leptin, resistin, and adiponectin.91,92
Adiponectin is an adipokine that has recently attracted much attention. There are two types 
of adiponectin: full-length adiponectin and globular adiponectin.93 Full-length adiponectin 
consists of an N-terminal collagen-like sequence and a C-terminal globular region, whereas 
globular adiponectin consists of a globular domain that is cleaved from the full-length 
protein by proteolysis.94 Almost all adiponectin appears to exist as full-length adiponectin in 
plasma. The physiological level of adiponectin in human serum has been reported to range 
from 5 to 30 μg/mL and is typically found at levels 35% lower in men than in women.95 
There is a tendency for reduced adiponectin levels in obese subjects.96–98 It is believed that a 
plasma level of adiponectin less than 6 μg/mL is related to obesity.97,99,100
Epidemiology
Almers et al.101 conducted a case-control study evaluating the association between 
adiponectin (total, high molecular weight, and low/medium molecular weight) and BE in the 
Kaiser Permanente Northern California population. Patients with a new diagnosis of BE 
were matched to patients with GERD (without BE) and to population controls. Serum 
adiponectin levels were found to be positively related to the risk of BE among patients with 
GERD, but not among population controls without GERD. Higher adiponectin levels were 
independently associated with aberrant healing of esophageal injury in GERD.
On the contrary, another recent study summarized data from nine observational studies (10 
independent cohorts; 1432 patients with BE and 3550 controls).102 When patients with BE 
were matched to population controls in five studies, subjects within the highest tertile of 
serum adiponectin level showed decreased odds of BE (OR 0.65; 95% CI 0.31–1.36). This 
association was even more pronounced in males. After adjustment for potential confounders, 
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such as age, sex, and race, the observed associations of adiponectin with BE remained 
significant.
In a third study from Taiwan, patients that had experienced typical GERD symptoms 
(heartburn and/or acid regurgitation) for at least three episodes per week in the past 3 months 
received a baseline assessment of symptom severity and frequency with the Reflux Disease 
Questionnaire and an upper endoscopy.103 GERD was classified into erosive esophagitis (n 
= 67), nonerosive esophagitis (n = 37), and BE (n = 8). These patients were measured for the 
serum levels of adipokines (adiponectin and leptin). No statistical difference was found in 
circulating adiponectin levels between the GERD and control groups, whereas BE patients 
had significantly lower adiponectin levels than those without BE.
Conflicting results derived from these studies may be due to the use of different controls and 
populations. In addition, the first study included only newly diagnosed BE, whereas the 
second study included both prevalent and newly diagnosed BE. Overall, a negative 
association between adiponectin and BE was found in the most epidemiological 
studies,103–105 suggesting that low adiponectin is associated with BE and may play a 
biological role in the pathogenesis of metaplasia.
Potential mechanisms
Numerous studies demonstrated that adiponectin might be a protective factor against 
mucosal inflammation and symptoms of GERD.106,107 Two types of adiponectin play 
different roles in inflammatory responses: full-length adiponectin has an anti-inflammatory 
effect, whereas globular adiponectin seems to have a proinflammatory effect in a reactive 
oxygen species (ROS)/NF-κB/p65–dependent manner.93 Globular adiponectin regulates 
proinflammatory cytokines, such as IL-6 and TNF-α.108 Full-length adiponectin reduces the 
activity of cytokine signaling and NF-κB.98,109,110 Previous studies found that adiponectin 
can inhibit leptin-induced signaling and inflammatory factors.111
Adiponectin receptors (AdipoR1 and AdipoR2) are expressed in normal squamous 
epithelium, BE, and EAC biopsies and cells.112–114 Globular adiponectin seems to mainly 
activate AdipoR1, whereas AdipoR2 engages mainly with full-length adiponectin.11. 
Konturek et al. examined expression of AdipoR1 and AdipoR2 in BE and matched normal 
esophageal biopsies from 15 patients. They found reduced expression of receptors in 
Barrett's mucosa relative to normal esophageal tissue. This observation suggests that the 
biological effect of adiponectin on the Barrett's mucosa of obese individuals may be 
attenuated.116
It is likely that, in obese patients with GERD, low adiponectin levels contribute to increased 
expression of proinflammatory cytokines, resulting in chronic inflammation.108 This 
persistent state of chronic inflammation gives rise to the release of proinflammatory 
mediators, which promote cell growth and invasion, thus supporting metaplasia and 
transformation. To summarize, the association between adiponectin and the metaplastic 
healing response (i.e., BE) suggests a potential mechanism linking obesity and esophageal 
injury.
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The section on stromal cells was written by Anisa Shaker; the interleukin 4 section was written by Tadayuki 
Oshima, Jing Shan, and Hiroto Miwa; and the section on adiponectin was written by Cheng Feng and Jun Zhang.
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We reviewed the roles of immunomodulators in GERD and BE by focusing on stromal 
cells, IL-4, and adiponectin. It has long been believed that targeting the 
immunomodulators or inflammation in general may improve therapeutic outcomes of 
GERD, particularly in patients refractory to PPIs. However the mechanisms are still not 
well understood. This is partially due to the complexity of molecular mechanisms of 
GERD. Isolating one factor out of many in mechanistic studies often endangers the 
physiological relevance of the discovery. The real challenge is how to translate laboratory 
research into the clinical setting, in particular, for diagnosis and treatment of GERD and 
its complications.
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Current and potential pharmacotherapy of GERD. TRPV1 and ASIC3 are two major 
receptors for chemical and mechanical stimuli leading to heartburn. Transient lower 
esophageal sphincter relaxation reducers failed in clinical trials. Mucosal protectants (e.g., 
Esoxx) are of limited efficacy.117 Epithelial enhancers, anti-inflammatory agents or SMG 
stimulants have not yet been developed to strengthen esophageal defense against GERD. 
Repamipide, an antiulcer agent acting through temporary stimulation of endogenous 
prostaglandins, has not been well studied for its potentially protective effect on esophageal 
epithelium
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Critical role of inflammation in the development of GERD and subsequent complications. 
This mechanistic model suggests that agents targeting immunomodulators or inflammation 
in general can be potentially used for GERD therapy.
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